% | $
Quotes you view appear here for quick access.


  • robert.vince robert.vince Mar 13, 2013 9:19 AM Flag

    Stellar Biotechnologies Announces Preclinical Poster at Society of Toxicology (SOT) Showing That Forms and Sources of KLH Matter

    PORT HUENEME, CA--(Marketwire - Mar 13, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") ( OTCQB : SBOTF ) ( TSX VENTURE : KLH ) today announced the presentation of results from a preclinical study of Keyhole Limpet Hemocyanin (KLH), conducted together with a partner, showing that manufacturing source and molecule form can impact the magnitude and consistency of antibody response to KLH.

    The abstract titled "T-Cell Dependent Antibody Responses in the Rat: Forms and Sources of KLH Matter" will be presented this week in a Poster session at the 52nd Annual Meeting of the Society of Toxicology (SOT) (March 10-14, 2013) at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

    KLH is used extensively in drug immunotoxicology to measure the T-cell dependent antibody response (TDAR). TDAR testing is widely recognized by regulatory agencies and drug developers worldwide as a standard method of assessing the suppressive effects of immunomodulating drugs on the immune system.

    In the study, anti-KLH IgM and IgG responses were measured in rats immunized with five different KLHs from three KLH commercial sources, including Stellar KLH. All test articles were administered without co-injection of an adjuvant. Dose analysis and biophysical characterization were also conducted. Among GMP grade KLHs tested in the study, Stellar HMW KLH and Stellar Subunit KLH elicited the greatest IgM and IgG responses. In addition, Stellar Subunit KLH elicited the greatest IgM and IgG responses compared to the subunit KLHs from other sources.

    "Stellar has long understood the impact that source and manufacturing process can have on the KLH molecule," said Herb Chow, Ph.D., Stellar Chief Technical Officer. "This data confirms our internal studies and our belief that Stellar's cGMP manufacturing processes deliver a more stable KLH with superior immunogenicity."

    The rapidly growing number of im

0.680.00(0.00%)May 13 9:02 AMEDT